A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).

Research output: Contribution to conferencePosterAcademic

Original languageEnglish
DOIs
Publication statusPublished - 2014
EventASCO 2014 -
Duration: 1 Jun 2014 → …

Conference

ConferenceASCO 2014
Period01/06/2014 → …

Cite this